Ozempic Teeth: What the Labels Say and What Reaches Your Enamel

Search "Ozempic teeth" and the same claim comes back in a hundred fonts: the shot is quietly dissolving enamel from the inside, one weekly dose at a time.

There are numbers on this, and they sit in the US prescribing information. In the pooled adult weight-reduction trials behind the semaglutide obesity label, 73% of patients on the injection reported gastrointestinal adverse reactions against 47% on placebo. Vomiting shows up at 25% versus 6%. Reflux has its own row. Gastric emptying slows down. Every one of those lines is describing the gut.

The erosion figures that get quoted back at you in the replies were measured somewhere else entirely — in dental journals studying stomach acid and saliva, in populations nobody assembled around a prescription. Two research trails, one nickname.

So where did "Ozempic teeth" come from?

The phrase is slang. The nearest thing it has to a definition sits in a 2026 narrative review in J Clin Med.

That review names the suspects: gastrointestinal adverse effects — nausea, vomiting, belching — plus reduced fluid intake and possible salivary changes. Those, in the authors' reading, underlie a cluster of patient-reported complaints colloquially termed Ozempic mouth, Ozempic teeth, and Ozempic breath. So the nickname has a shape. The same authors also attach a warning to it:

Human oral-health-endpoint data remain scarce; much evidence is preclinical, indirect, or derived from case-level or pharmacovigilance reports.

That sentence stays attached to everything below.

The nickname has a second wrinkle in it. In the US, Ozempic is the semaglutide injection indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The conversation that borrowed the name is mostly about weight. A diabetes brand got stapled onto a weight-management experience. The mismatch starts to matter the moment anyone compares figures, because the diabetes label and the obesity labels report different trials.

The labels describe a slower stomach

The labels state the pharmacology one molecule at a time. Semaglutide delays gastric emptying. The semaglutide obesity label carries that line in clinical pharmacology, section 12.2; the Ozempic injection label files the same fact under drug interactions, section 7. The tirzepatide obesity label says tirzepatide delays gastric emptying, and adds a detail worth holding onto: the delay is largest after the first dose and this effect diminishes over time.

Tirzepatide, by the way, isn't a pure GLP-1 at all. It's a dual agonist, GIP as well as GLP-1, and it comes with its own document, its own tables, and its own numbers.

Slower emptying is the mechanism in writing. Getting from there to a tooth takes one more step. The labels supply that step as rows — vomiting and gastroesophageal reflux disease each have their own line in the adverse-reaction tables.

Vomiting and reflux, row by row

Back to those percentages, with the rest of the row attached. The semaglutide obesity label pools its adult weight-reduction trials, and the gastrointestinal reactions it reports most often are nausea (44% vs 16%), vomiting (25% vs 6%), and diarrhea (30% vs 16%). Each pair is one arm's own incidence — not a difference, not a sum.

Dosage form does more work here than you'd expect. That label covers an injection and a tablet, and reports them separately. Every semaglutide obesity figure here comes from the injection side.

The tirzepatide columns hold 958 patients on placebo and 630, 948, and 941 across the three doses. The Ozempic columns run 262, 260, and 261. The section around the tirzepatide table adds the timing: the majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time. If your worst weeks were the weeks the dose went up, that's the pattern the label describes.

One thing that table isn't: a ranking. Three labels, three trial programs, three ways of pooling, two different indications. A column from one document doesn't line up against a column from another. Nothing here is a head-to-head comparison.

What stomach acid does once it reaches enamel

Now the subject changes, and so does the population. A 2008 systematic review in Aliment Pharmacol Ther gathered 17 studies of dental lesions in gastroesophageal reflux disease, and put the median prevalence of dental erosion in those patients at 24%, across a wide range of 5 to 47.5%. Read it the other direction and the median prevalence of reflux disease in adults who already had dental erosion was 32.5%.

A 2024 systematic review in J Dent takes the same territory from a different angle: association rather than prevalence. It included 87 publications reporting on 71 studies, and it ran random-effects odds-ratio meta-analyses where that was possible rather than across every risk factor it screened. Erosive tooth wear showed significant associations with regurgitation (odds ratio 2.27, 95% confidence interval 1.41 to 3.65) and with digestive disorders (odds ratio 1.81, 1.48 to 2.21).

Neither paper studied anybody's prescription. The 2008 population was defined by reflux; the 2024 odds ratios came out of observational studies that were never selected for a weight-management drug either. An odds ratio measures association, not the chance that something happens to you, and 2.27 does not translate into "2.27 times more likely to lose a tooth."

The bridge from a vomiting row in a drug label to an erosion figure in a dental journal is an editorial one — drawn here, not by either source. The grade on it is the line the 2026 review wrote for its own evidence: human oral-health-endpoint data remain scarce.

The tirzepatide obesity label puts a number on a dry mouth

In a pool of the label's Study 1 and Study 2, dry mouth or dry throat was reported by 1% of tirzepatide-treated patients and 0.1% of placebo-treated patients.

Two caveats travel with it. The label term combines mouth and throat, and the number belongs to that molecule and that document — it isn't a class-wide figure, and it doesn't slide over onto semaglutide.

Alongside the label figure sits a much smaller kind of paper. A 2023 case series in Medicine (Baltimore) describes three patients who had been using semaglutide for weight loss for a mean duration of 11.3 weeks and turned up with xerostomia — the clinical word for a dry mouth. Other possible underlying medical problems were excluded first. Then came the diagnosis the authors gave them: semaglutide-induced hyposalivation, with a mean modified Schirmer test of 9 mL at 3 minutes. The paper's own title uses the softer word: semaglutide-associated.

Three people is three people. That's a count, not a rate, and turning it into a percentage would invent arithmetic nobody performed.

The jobs saliva is doing in there

A 2014 review in Monogr Oral Sci calls saliva the most relevant biological factor for the prevention of dental erosion, then lists the work it does. It starts before the acid lands, with flow rate rising in response to acidic stimuli. It buffers. It dilutes and clears the acids that come into contact with dental surfaces. It forms the acquired dental pellicle, a membrane that keeps acid off the tooth. And thanks to its mineral content, it can prevent demineralization as well as enhance remineralization. The same review notes that these protective properties may become more evident in hyposalivatory patients.

Less saliva means less of all of that, at exactly the moment the acid question is live — which is why a dry mouth belongs in an article about vomiting rather than in a beauty column.

Fluids show up on the label as a medical instruction. The patient-counseling section of the semaglutide obesity label tells prescribers to inform patients of one specific risk: acute kidney injury due to dehydration associated with gastrointestinal adverse reactions. It also tells them to advise patients to take precautions to avoid fluid depletion. Diarrhea, nausea, and vomiting cost you fluid. The label treats that as a kidney question first and a comfort question second.

Rinsing with water after a rough episode isn't a study finding. It's the dilution-and-clearance line from that saliva review, applied with ordinary common sense.

Does waiting to brush actually help?

The other half of the folklore is about what you do next, and almost everyone has heard it: after acid, don't brush right away — wait a while first.

A 2020 systematic review and meta-analysis in Clin Oral Investig compared brushing straight after an erosive attack with brushing later, and the waiting did not earn its reputation. No significant difference in the erosive tooth wear of human enamel was observed between delayed and immediate toothbrushing. The conclusion is blunt: delayed toothbrushing alone after the consumption of erosive foodstuffs or beverages is not capable of preventing erosive enamel wear.

The same paper did find something. In its subgroup analyses, the use of fluoridated toothpaste made a significant contribution to decreasing the erosive tooth wear of human enamel after erosion and toothbrush abrasion.

One paper. One main result, one subgroup analysis. Not two studies arguing with each other — the same authors finding nothing in the waiting, and something in the fluoridated toothpaste.

The scope matters. Those were in situ and in vitro studies about erosive foods and drinks, and human enamel was one of three tissue arms analyzed separately. It's dental science about acid, standing next to drug labels about vomiting.

What the two flagship weight trials signed up to measure

A trial registry is a colder document than any of this. It says in advance what a trial set out to measure.

That's a scope statement. Both records are public under those ID numbers.

Before a dental appointment with sedation

Here the labels stop describing and start instructing.

Both the US semaglutide obesity label and the US tirzepatide obesity label describe rare postmarketing reports of pulmonary aspiration. The patients in those reports were receiving GLP-1 receptor agonists — the labels' phrase — and undergoing elective surgeries or procedures requiring general anesthesia or deep sedation. They had residual gastric contents despite reported adherence to preoperative fasting recommendations. Both labels then instruct patients to inform healthcare providers prior to any planned surgeries or procedures.

In a dental context that collapses into one sentence at the front desk. Wisdom teeth, implants, anything where you go under: the labels want your GLP-1 mentioned while the appointment is being booked. The wording covers any planned surgery or procedure, so there's no harm in saying it at a routine cleaning either. What happens next belongs to the dental team and your prescriber, never to a checklist on a blog.

A few other lines in those labels have nothing to do with toothbrushes. They're the ones worth knowing cold.

Two of those rows need plain language. A personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, is a hard stop for both obesity drugs. The label's phrase is personal or family history, so it isn't only about your own chart. Acute pancreatitis is one tier lower: a warning rather than a contraindication, with a label instruction to stop the drug and start appropriate management on suspicion. Abdominal pain that is severe or persistent is a call to your prescriber or to emergency care. Vomiting or diarrhea that won't let up belongs in the same category, for the same fluid reason.

Boxed warning is US FDA label language. The EMA, MHRA, PMDA, and other regulators publish their own product information, with their own wording and their own approved indications. A US obesity brand isn't automatically the brand — or the indication — sold where you live.

Two habits, and five questions worth asking out loud

Two behaviors survive all of that, and both are small. Fluoridated toothpaste is the one with a finding behind it — the subgroup analysis in that human-enamel meta-analysis. Water is the other. For the mouth, because dilution and clearance are saliva's jobs and a dry mouth does less of both; for the rest of you, because the label treats fluid depletion during gastrointestinal reactions as a kidney risk.

Everything else here is a conversation:

• "The dose went up last month and I've been vomiting since — is that the escalation pattern, or something else?"
• "My mouth is dry most of the day now. Is that worth looking at, and what else could be causing it?"
• "I'm scheduled for an extraction with sedation. What do you and my dentist need to know before that day?"
• "Reflux has been waking me at night. Does that change anything about the dose or the timing?"
• "What symptoms mean call you today instead of waiting for the next appointment?"

Cost is its own conversation in the US, where dental coverage usually sits in a separate policy from medical, and repair work lands out of pocket. On the drug side, the US list price for semaglutide (Wegovy) runs around $1,349 a month, and what anyone actually pays swings hard with the plan, the clinic, the prior authorization, and the dose. Those two budgets don't talk to each other, which is one more reason to raise the mouth question early.

What the prescribing information puts in writing is a slower stomach, a vomiting row, a reflux row, and the tirzepatide label's dry-mouth figure. Next to it is a dental literature that measured what acid and low saliva do once they arrive.

The labels quoted here are the US versions in effect as this was written, and labels get revised. None of these documents — the trials, the registries, the reviews, the prescribing information — can see your history, your dose, or the wear on your molars. The dentist looking in your mouth can, and so can the prescriber managing the dose. Neither of them needs a new appointment to hear about the other; the one already on your calendar will do.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app